Tagrisso Osimertinib 80mg Tablets

Introduction to Tagrisso 80mg 

Tagrisso 80mg is a targeted therapy designed to treat certain types of non-small cell lung cancer (NSCLC) that have mutations in the epidermal growth factor receptor (EGFR) gene. AstraZeneca Pharma India manufactures Tagrisso 80 mg. Tagrisso 80mg tablets contain the active component Osimertinib. EGFR is a protein that plays a key role in cell growth and division. In the case of an EGFR mutation, cancer cells can multiply uncontrollably. This tablet works by inhibiting the activity of this mutated EGFR, thereby stopping or slowing the growth of cancer cells.  The FDA approved Tagrisso based on clinical trials for EGFR-mutated lung cancer in several scenarios. 

Uses of Tagrisso 80mg 

• As an adjuvant therapy after complete surgical removal of the tumor.
• As a first-line treatment for metastatic NSCLC (when the cancer has spread to other parts of the body).
• As a treatment for metastatic NSCLC that has worsened during or after using other similar medications.

How Tagrisso 80mg Tablet Works

Tagrisso 80mg Tablet is an anti-cancer medication that targets specific mutations in the epidermal growth factor receptor (EGFR). It works by blocking the activity of abnormal EGFR proteins, which signal cancer cells to grow and multiply. By inhibiting these signals, Tagrisso helps to slow or stop the growth and spread of cancer cells, particularly in patients with non-small cell lung cancer (NSCLC) that carry certain EGFR mutations.

Administration of Tagrisso 80mg Tablet

Take Tagrisso 80mg Tablet exactly as prescribed by the patient's doctor, in the recommended dose, and for the specified duration. Swallow the tablet whole; do not chew, crush, or break it. Tagrisso can be taken with or without food, but it is important to take it at the same time each day for the best results. Always follow the patient's doctor's instructions and recommendations for proper use. 

Side Effects of Tagrisso 80 mg Tablets 

• Diarrhea
• Loss of appetite
• Rash
• Inflammation of the mouth

• Risk of Infection
• Bruising and bleeding
• Sore throat or mouth ulcers
• Dry skin
• Nail toxicity 
• Fatigue 
• Decreased appetite
• Low blood cell counts
• Anemia 

Benefits of Tagrisso 80mg Tablet in Non-Small Cell Lung Cancer (NSCLC)

Tagrisso 80mg Tablet, containing Osimertinib, is an effective treatment for certain types of EGFR-positive NSCLC. It can be used alone or in combination with other medications, depending on the specific case.

Tagrisso works by targeting and blocking proteins in cancer cells that promote cancer growth. By doing so, it can help to slow or stop the progression of advanced lung cancer. In addition to treating existing cancer, Tagrisso may be used after surgery to help prevent the cancer from returning.

Interaction of Tagrisso 80mg Tablet with other drugs 

It is important to inform the patient’s healthcare specialist about all the medications you are taking before starting Tagrisso 80mg Tablet, as certain drugs can interact with it and affect its effectiveness. Some antifungal medications like ketoconazole and itraconazole may increase the risk of side effects by raising Tagrisso levels in the blood, while anticonvulsants such as phenytoin and carbamazepine can reduce their effectiveness. Antibiotics like rifampin, and proton pump inhibitors (PPIs) like omeprazole can also interfere with Tagrisso’s function. Additionally, taking blood thinners such as warfarin alongside Tagrisso may increase the risk of bleeding. Always consult a patient's doctor before starting or stopping any medication while on Tagrisso to avoid potential interactions.

Precautions while taking Tagrisso 80 mg tablets

 The safety of consuming alcohol while taking Tagrisso 80mg Tablet is not established. 

 Tagrisso 80mg Tablet may not be safe during pregnancy. 

 This Tablet is likely unsafe during breastfeeding. Limited human data suggests that the drug may pass into breast milk and could harm the baby.

 Tagrisso 80 Tablet does not usually impair a patient's ability to drive. 

 This tablet is considered safe for patients with kidney disease

 Tagrisso 80mg Tablet is safe for patients with liver disease. No dose adjustment is needed.